|Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).|
|Jump to Full Text|
|PMID: 21350895 Owner: NLM Status: MEDLINE|
|INTRODUCTION: Regulation (EC) no. 1924/2006 on nutrition and health claims targeting food products was introduced in Europe stating that health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. The objective of this paper is to define health claims related to bone health and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims.
METHODS: Literature review followed by a consensus discussion during two 1-day meetings organized by the Group for the Respect of Ethics and Excellence in Science (GREES).
RESULTS: The GREES identified six acceptable health claims related to bone health based on the potential of food products to show an effect on either the bioavailability of calcium or osteoclast regulatory proteins or bone turnover markers or bone mineral density or bone structure or fracture incidence. The GREES considers that well-designed human randomized controlled trial on a relevant outcome is the best design to assess health claims. The substantiation of health claim could also be supported by animal studies showing either an improvement in bone strength with the food product or showing the relationship between changes induced by the food product on a surrogate marker and changes in bone strength.
CONCLUSION: The consensus reached is that the level of health claim may differ according to the surrogate endpoint used and on additional animal studies provided to support the claim.
|O Bruyère; R Rizzoli; V Coxam; B Avouac; T Chevalier; V Fabien-Soulé; J A Kanis; J-M Kaufman; Y Tsouderos; J-Y Reginster|
Related Documents :
|15466095 - Follow-up after a pediatric emergency department visit: telephone versus e-mail?
24596875 - The errors of individualistic public health interventions: denial of treatment to obese...
15508195 - Improving antimicrobial use among health workers in first-level facilities: results fro...
2691465 - Hospitalization of adolescents for psychiatric and substance abuse treatment. legal and...
8187705 - Chlorinated dioxins and dibenzofurans in human tissue from general populations: a selec...
2145505 - Trends in the prevalence of work disability from 1962 to 1984, and their correlates.
|Type: Consensus Development Conference; Journal Article Date: 2011-02-25|
|Title: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Volume: 23 ISSN: 1433-2965 ISO Abbreviation: Osteoporos Int Publication Date: 2012 Jan|
|Created Date: 2012-01-02 Completed Date: 2012-03-21 Revised Date: 2013-06-30|
Medline Journal Info:
|Nlm Unique ID: 9100105 Medline TA: Osteoporos Int Country: England|
|Languages: eng Pagination: 193-9 Citation Subset: IM|
|Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Bone Remodeling / physiology
Bone and Bones / metabolism, physiology*
Evidence-Based Medicine / methods
Food Industry / legislation & jurisprudence
Functional Food / standards*
Guidelines as Topic
Nutritional Physiological Phenomena / physiology*
Journal ID (nlm-ta): Osteoporos Int
Publisher: Springer-Verlag, London
© The Author(s) 2011
Received Day: 4 Month: 1 Year: 2011
Accepted Day: 26 Month: 1 Year: 2011
Electronic publication date: Day: 25 Month: 2 Year: 2011
pmc-release publication date: Day: 25 Month: 2 Year: 2011
Print publication date: Month: 1 Year: 2012
Volume: 23 Issue: 1
First Page: 193 Last Page: 199
PubMed Id: 21350895
Publisher Id: 1561
|Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)|
|J. A. Kanis7|
1Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
2Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland
3Department of Human Nutrition, University of Clermont Ferrand, Clermont Ferrand, France
4CHU Henri Mondor, Paris, France
5Theramex, Monte Carlo, Monaco
6Rousselot, Nanterre, France
7WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
8Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, Ghent, Belgium
9Servier, Paris, France
More and more food products bear health claims. The skepticism of consumers regarding functional foods is mainly due to doubts over the veracity of health claims and in the poor and often inadequate control of their claimed properties. It is important that health claims should provide genuine information to help consumers choose healthy diets. Consequently, claims should be supported by a sound and sufficient body of scientific evidence to substantiate them and be reinforced by specific consumer education.
Since health claims on food products are increasingly recognized to be important, they are being legally regulated in more and more countries around the world . Although there is a general scientific consensus on how to substantiate health claims on food , there is no agreement on the specific approaches and indicators that can be used in different fields. Various jurisdictions have developed systematic approaches for reviewing scientific data linking food products and health with the objective of identifying the threshold of scientific evidence needed to substantiate an authoritative statement to the general public in the form of a label claim for a given marketed food product. In Europe, a regulation on nutrition and health claims made on foods was introduced in 2007. This regulation provides opportunities for the use of health claims on foods in Europe, including reduction of disease risk . According to Regulation EC 1924/2006, the use of nutrition and health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. A community list of permitted and rejected claims has been established and made available to the public (http://ec.europa.eu/food/food/labellingnutrition/claims/community_register/health_claims_en.htm).
The regulation defines a health claim in general as “any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health.” All claims are addressed in Articles 13 and 14 of the Regulation EC 1924/2006 (Table 1).
In the context of health claims in foods, bone health is of potential interest as it is a major public health problem, at least in Western countries . Up to 60% of the variance in bone mass is determined by genetic factors. Environmental factors account for the remainder, including nutritional intake and lifestyle habits throughout life [5, 6].
In the field of bone health, there are no scientifically based definitions of health claims and no uniform recommendations of the preferred study and/or methodology, even though some preparatory work had been done before the introduction of the European regulations . The objective of this paper was to define the relevant biomarker for bone health and to provide recommendations for the design and the methodology of clinical studies which need to be fulfilled to assert claims related to bone health. The intent was to aid regulatory authorities in defining claims and assessing scientific evidence used to support those that relate to bone health. By establishing common criteria for these assessments, it is hoped that these recommendations will lead to harmonization of the requirements for scientific substantiation of claims worldwide.
Two 1-day meetings were organized by the Group for the Respect of Ethics and Excellence in Science (GREES). This non-for-profit organization has expertise in literature research and consensus meetings. The meetings were attended by academic scientists with expertise in the field of bone health or nutrition, members of regulatory authorities as well as industrialists with interests in health claims relating to bone. The objective of the first day of the meeting was to critically review the current literature in the field of health claims related to bone and to discuss the needs and problems to assert such claims. The objective of the second day was to reach consensus on scientifically acceptable health claims related to bone and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims.
A literature search, using Medline database up to August 2010, was performed using keywords including health claims, nutrition, bone, osteoporosis, clinical study methodology, surrogate endpoint. A selection of relevant papers was made by OB, RR, and JYR.
The GREES panel considers that clinical data in humans are indispensable, and that health claims cannot be accepted solely on the basis of animal data. However, as discussed below, animal studies can give important information not available in humans and can provide data for the generalization of results obtained in a specific tested population to a larger group. Thus, different levels of heath claims should be considered based both on the endpoint used and on the information provided by animal studies.
A variety of invasive and non-invasive techniques can be used to provide relevant endpoints [4, 7], including bioavailability studies, microarray or PCR analysis of modulated genes, histomorphometry, culture of bone forming or bone resorbing cells ex vivo, exposure to primary cell cultures to plasma harvested from treated animals, the chemistry and biochemistry of bone tissue, the assessment of biochemical indices of skeletal turnover in blood and urine, metabolic balance of calcium combined with radioactive calcium kinetics, radiogrammetry of bone radiographs, neutron activation for whole body calcium, dual x-ray absorptiometry (DXA), and the assessment of bone strength . The latter endpoint is considered to be the most relevant in the field of bone health claims. Bone strength reflects both bone density and bone quality. Bone quality depends on bone architecture, mineralization, turnover, and accumulation of microdamage. Therefore, the assessment of bone health would benefit from the measurement of bone strength in vivo. No validated non-invasive tools capable of measuring bone strength in vivo are available to date. However, biomechanical tests of resistance to fracture provide an objective measure of overall bone strength. The three main types of biomechanical tests for bone strength are bending, torsional, and compression tests . It is considered that both long bones and vertebral bodies should be tested since they may be differentially affected by food products.
Besides the assessment of a direct effect of the food product on bone strength, two other aims of animal data could be to better understand the mechanism of action of the food product or to validate surrogate variables used in human animal data to see if these variables reflect bone strength.
Key criteria of suitable/acceptable animal studies are:
- ➢to deliver the food product in the manner in which it will be delivered in a human setting;
- ➢to utilize a site of delivery and/or assessment site that is as closely matched as possible to the settings in which it will be used;
- ➢to utilize an animal that provides a metabolic background and physiological responsiveness comparable to humans;
- ➢to utilize a formulation of active agent that has the same composition, release, retention, and degradation properties as the formulation that will be used in humans.
The GREES panel considers that six different health claims could be accepted for an effect of food products on bone health. However, as already used by the European Food and Safety Authority, different wording to reflect the level of evidence of the effect could be used depending on the effect that is (always), may (demonstrated only under certain circumstances) or might be (logically expected benefit from physiology but yet not demonstrated) beneficial for bone health.
- Improvement of calcium bioavailability
Calcium bioavailability may be defined as the proportion of calcium in foods which is absorbed and utilized for normal metabolic functions. In addition to the amount of calcium in the diet, the fractional absorption of dietary calcium in food and its retention in the body are also a factor that determines the availability of calcium for bone development and maintenance of bone health [10, 11]. Many methods can be used to assess bioavailability (i.e., classical and isotopic balances, urinary excretion, isotope labeling in the urine, plasma, and bones) . The group considers that an increase in bioavailability is not beneficial if not accompanied by calcium retention in the body. A food product with an effect on calcium bioavailability with or without calcium retention data, unless associated with appropriate animal studies would not fulfill a claim related to article 14. However, food products that show an effect on bioavailability and calcium retention could have an article 13 claim: “X increases calcium absorption” or “X increases calcium bioavailability”.
- Maintenance of bone metabolism (through an effect on osteoclast regulatory proteins)
The transition of osteoclast precursors to mature osteoclasts that are capable of resorbing bone is tightly regulated by osteoclast regulatory proteins that either affect the differentiation and proliferation of osteoclast precursors into mature osteoclasts or are involved in the coupling between osteoblasts and osteoclasts . Markers of osteoclastogenesis include receptor activator of nuclear factor kappa-B ligand and osteoprotegerin, whereas markers of osteoclast number include tartrate-resistant acid phosphatase and cathepsin K. These proteins contribute to bone metabolism but are not yet strongly associated with elements of bone strength. A food product with an effect on osteoclast regulatory proteins, unless supported by animal studies (see next BMD and BTM sections) would not fulfill a claim related to article 14. The product, however, might have the label under the article 13: “X contributes to the maintenance of bone metabolism”.
- Maintenance or changes in bone turnover marker
A determinant of bone strength that is not assessed by bone mineral density (BMD) is the rate of bone remodeling. Depending upon their origin, bone turnover markers (BTMs) are classified as indices of bone resorption or formation [14–17]. The rate of bone resorption and formation can be estimated by assays that measure the serum concentration or urinary excretion of different target molecules specific to these cellular processes. GREES panel recommends the inclusion of reference markers of bone formation (serum procollagen type I N propeptide, s-PINP) and resorption (serum C-terminal cross-linking telopeptide of type I collagen, s-CTX) in keeping with the recommendations of the International Osteoporosis Foundation . A food product with a positive BTM balance might have the claim: “X maintains normal bone remodeling that could contribute to the normal structure and function of bones” or “X increases markers of bone formation that could contribute to the normal structure and function of bones” or “X decreases markers of bone resorption that could contribute to the normal structure and function of bones”.
As in the case of BMD, BTMs are only indicators of fracture risk, but the change in BTM induced by a product is not necessarily associated with a change in fracture risk or bone strength. In this regard, animal models are useful to assess if changes in BTMs due to the intake of the food product are associated with an increase in bone strength. A food product with an effect on BTMs together with animal studies that showed improved bone strength or a relationship between changes in BTMs induced by the food product and bone strength could have the claim: “X contributes to the maintenance of normal bone remodeling (or increases bone formation or decreases bone resorption) that is associated with bone strength” or “X contributes to the maintenance of normal bone remodeling (or increases bone formation or decreases bone resorption) that increases bone strength” or “X increases bone strength”.
- Maintenance or improvement in bone structure
The key role of bone microarchitecture in bone health was suggested by the classic definition of osteoporosis adopted in 1993 . Methods for investigating 3-D bone microarchitecture and bone strength include in vitro μCT, in vitro μMRI, in vivo pQCT, and in vivo high-resolution MRI . They aim to quantify various determinants of bone strength such as bone geometry, volumetric bone density, microarchitecture, and properties of the bone matrix . A food product with an effect on bone microarchitecture could have the claim: “X improves (or maintains) bone microarchitecture that could contribute to the normal structure and function of bones”.
It is considered that the assessment of bone structure with the tools currently available in man is not sufficiently validated to be a reliable surrogate of bone strength. For this reason, animal models are needed to assess the relationship between changes in bone microarchitecture induced by the food product and any increase in bone strength. A food product with an effect on microarchitecture of the human bone and animals studies that show improvement in bone strength or show the relationship between change in bone structure induced by the food product and bone strength could have the claim: “X improves bone microarchitecture that increases bone strength” or “X increases bone strength”
- Maintenance or increase in bone mineral density
Bone strength is determined by many factors, including bone mass. Bone mass is estimated in clinical practice by the measurement of BMD. BMD, as measured by DXA, represents an estimate of the quantity of mineral (grams of calcium) divided by the two-dimensional area of the bone . There is a strong relationship between the risk of fracture and BMD but there is a wide overlap in the bone densities of patients who develop a fracture and those who do not. Since BMD is only a surrogate marker for bone strength or fracture risk, and since product-induced changes in BMD are not clearly associated with changes in bone strength or fracture risk, an increase in BMD may not be associated with an increased bone strength or decreased fracture risk . A food product with a positive effect on BMD could have the claim: “X increases BMD. A low BMD is associated with an increased risk of fracture” or “X maintains BMD. A low BMD is associated with an increased risk of fracture”.
Animal models are appropriate to determine whether an increase in BMD associated with a food product is accompanied by an increase in bone strength. A food product with a positive effect on BMD, together with animal studies showing an improvement in bone strength or showing a relationship between BMD changes induced by the food product and bone strength, could have the claim: “X increases (or maintains) BMD that could reduce the risk of fracture” or “X increases (or maintains) BMD that increases bone strength” or “X increases bone strength”.
- Reduction of the risk of fracture
A reduction of the incidence of fracture is a major aim of food products beneficial to skeletal health, but according to the regulation cannot be claimed as such without mentioning the effect on a risk factor. However, a reduction in the fracture risk is obviously supportive for a claim on the reduction of an identified risk factor. For non-spinal fractures, either femoral (hip) or major non-vertebral (pelvis, distal femur, proximal tibia, ribs, proximal humerus forearm, and hip) fractures should be assessed.
The subjects studied should be representative of the population targeted for the food product. The applicant should take all necessary precautions to make sure that the tested population is equivalent to the user population with respect of ethnicity, age, physiological status (such as menopause for example), life habits (such as exercise) and diet. No densitometric criteria are required for inclusion. However, the experimental and the control group must show no significant differences in term of baseline BMD.
The ideal design would be a multicentre randomized controlled study (RCT). The control could be a placebo, another active product or nothing, depending on the tested food. When possible, subjects and/or investigators should be blinded of the intervention. Treatment and control groups should be balanced with respect to gender, age, menopausal status, dietary habits, or underlying diseases. The GREES panel recognizes that a RCT is not always possible in practice or from an ethical point of view. Since the totality of the evidence should be weighed for the substantiation of a claim, well-designed prospective cohort studies, case–control studies and/or observational studies of high quality could be acceptable if accompanied by other data (e.g., animal data, effect on multiple surrogate endpoints). Cross-over studies design can also be considered. All the efforts should be made to eliminate potential confounders.
- Duration of study
The duration of the trial should be predetermined and should depend on the outcome. For BMD, duration of at least 1 year seems necessary. For BTMs, a 3-month study is the minimum. The primary efficacy endpoint should be assessed at the end of the predetermined treatment period in comparison with the measurement at baseline. Intermediate measurements are also recommended.
- Statistical analysis
Intention-to-treat analysis should be the primary method of evaluation. Statistical significance will be inferred if a P value is equal to or less than 0.05. The beta risk will be equal to or less than 20%. The sample size of the study must be calculated prior to the start of the study. Possible confounding variables should be managed using appropriate statistical analysis. Within group (end vs. baseline) and between groups comparisons should be made.
- Diet habit and lifestyle
The control of critical effect modifiers such as physical activity, synergies with a multitude of other nutrients and the influence of nutrigenomic relationships must be taken into account.
Intakes of other nutrients or foods, on which the tested nutrient is dependent, must be optimized. Any supplementation with other food products known to have an effect on bone (e.g., calcium and/or vitamin D) should be consistent within all patient groups.
Observance of food product intake should be monitored during the study to be able to perform pre-planned analyses on individuals with high and poor compliance rates or analyses of dose–response.
All adverse experiences occurring during the course of clinical trials should be fully documented with separate analysis of adverse events, dropouts, and patients who died while being on the study.
According to the European regulation, the use of nutrition and health claims shall only be permitted if the food product has been shown to have a beneficial nutritional or physiological effect in agreement with the health claim. However, it must also be pointed out that during the evaluation of the health claim, besides the characterization of the effect, important elements will be taken into account, such as the characterization of the food and the substantiation of the effect. In the field of bone health, claimed effects are not sufficiently defined and there are no standardized recommendations for the design and the methodology of clinical studies needed to reach such health claims. The consensus reached by the GREES is that the level of health claim may differ according to the surrogate endpoint used and on additional animal studies provided to support the claim. The ideal study design is a RCT but, is some particular cases, prospective cohort, case-control, or observational studies can be acceptable. In our opinion, general principles of the consensus reached are in line with the principles adopted in the EFSA's published opinions. This consensus is subject to future modifications when new validated surrogate markers will be available.
The authors would like to thank Professor Ambroise Martin, from University Claude Bernard in Lyon, France, and member of the NDA panel of the EFSA, for participation in the meetings.
Conflicts of interest O Bruyere receives grants or has been reimbursed for attending meetings from GlaxoSmithKline, IBSA, MSD, Novartis, Rottapharm, Servier, Theramex and Wyeth. He also gives advice to the European Food Safety Authority and the French Food Safety Agency. R Rizzoli is at the Speaker Bureau of Amgen, GSK, Merck, Novartis, Nycomed, Roche, and Servier. He is a member of the Scientific Advisory Boards of Amgen, Danone, Eli Lilly, Novartis, Nycomed, Roche, and Servier; and editor of Bone and Associate Editor of Osteoporosis International. He is treasurer and member of the Executive Committee of the International Osteoporosis Foundation. V Coxam receives grants from Danone, Greentech, Lesieur, Rousselot and Servier. B Avouac received fees from Servier, Novartis, Negma, Amgen, GlaxoSmithKline, Roche, Nycomed, Theramex, UCB, Expanscience, Lundbeck, Janssen Cilag and Horus. JA Kanis consults for a large number of companies and receives grants or gives advice to nongovernmental agencies. JM Kaufman received fees as consultant or received financial support for attending meetings from Amgen, Eli Lilly, GlaxoSmithKline, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Nycomed, Procter & Gamble, Roche, Sanofi-Aventis, Servier, and Wyeth. He received grant support from GlaxoSmithKline, Merck Sharpe & Dohme, Novartis, Roche, and the Flemish Fund for Scientific Research. He is a (alternate) member of a commission on drug reimbursement with the Belgian health authorities. J-Y Reginster has received consulting fees or payments for participating in advisory boards for Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, and UCB. He has received lecture fees when speaking at the invitation of Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, and Novo Nordisk; and grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, and Servier.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
|1..||Jones PJ,Asp NG,Silva P. Evidence for health claims on foods: how much is enough? Introduction and general remarksJ NutrYear: 20081381189S1191S18492855|
|2..||Grossklaus R. Codex recommendations on the scientific basis of health claimsEur J NutrYear: 200948Suppl 1S15S2210.1007/s00394-009-0077-z19937439|
|3..||Asp NG,Bryngelsson S. Health claims in Europe: new legislation and PASSCLAIM for substantiationJ NutrYear: 20081381210S1215S18492859|
|4..||Prentice A,Bonjour JP,Branca F,Cooper C,Flynn A,Garabedian M,Muller D,Pannemans D,Weber P. PASSCLAIM—bone health and osteoporosisEur J NutrYear: 200342Suppl 1I28I4912664322|
|5..||Rizzoli R. Nutrition: its role in bone healthBest Pract Res Clin Endocrinol MetabYear: 20082281382910.1016/j.beem.2008.08.00519028358|
|6..||Rizzoli R,Bianchi ML,Garabedian M,McKay HA,Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderlyBoneYear: 20104629430510.1016/j.bone.2009.10.00519840876|
|7..||Bonjour JP,Ammann P,Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelinesOsteoporos IntYear: 1999937939310.1007/s00198005016110550456|
|8..||Muschler GF,Raut VP,Patterson TE,Wenke JC,Hollinger JO. The design and use of animal models for translational research in bone tissue engineering and regenerative medicineTissue Eng Part B RevYear: 20101612314510.1089/ten.teb.2009.065819891542|
|9..||Ammann P. Bone strength and ultrastructureOsteoporos IntYear: 2009201081108310.1007/s00198-009-0866-519340499|
|10..||Cashman KD. Calcium intake, calcium bioavailability and bone healthBr J NutrYear: 200287Suppl 2S169S17710.1079/BJN/200253412088515|
|11..||Fairweather-Tait SJ,Teucher B. Calcium bioavailability in relation to bone healthInt J Vitam Nutr ResYear: 200272131810.1024/0300-98220.127.116.111887747|
|12..||Gueguen L,Pointillart A. The bioavailability of dietary calciumJ Am Coll NutrYear: 200019119S136S10759138|
|13..||Leeming DJ,Alexandersen P,Karsdal MA,Qvist P,Schaller S,Tanko LB. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practiceEur J Clin PharmacolYear: 20066278179210.1007/s00228-006-0174-316912870|
|14..||Civitelli R,Armamento-Villareal R,Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practiceOsteoporos IntYear: 20092084385110.1007/s00198-009-0838-919190842|
|15..||Brown JP,Albert C,Nassar BA,Adachi JD,Cole D,Davison KS,Dooley KC,Don-Wauchope A,Douville P,Hanley DA,Jamal SA,Josse R,Kaiser S,Krahn J,Krause R,Kremer R,Lepage R,Letendre E,Morin S,Ooi DS,Papaioaonnou A,Ste-Marie LG. Bone turnover markers in the management of postmenopausal osteoporosisClin BiochemYear: 20094292994210.1016/j.clinbiochem.2009.04.00119362543|
|16..||Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosisCrit Rev Clin Lab SciYear: 20084522125810.1080/1040836080194944218415816|
|17..||Vasikaran SD,Glendenning P,Morris HA. The role of biochemical markers of bone turnover in osteoporosis management in clinical practiceClin Biochem RevYear: 20062711912117268580|
|18..||Vasikaran SD,Eastell R,Bruyere O,Foldes AJ,Garnero P,Griesmacher A,McClung M,Morris HA,Silverman S,Trenti T,Wahl DA,Cooper C,Kanis JK. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standardsOsteoporos IntYear: 201122239142010.1007/s00198-010-1501-121184054|
|19..||Consensus development conferenceDiagnosis, prophylaxis, and treatment of osteoporosisAm J MedYear: 19939464665010.1016/0002-9343(93)90218-E8506892|
|20..||Lespessailles E,Chappard C,Bonnet N,Benhamou CL. Imaging techniques for evaluating bone microarchitectureJoint Bone SpineYear: 20067325426110.1016/j.jbspin.2005.12.00216497531|
|21..||Brandi ML. Microarchitecture, the key to bone qualityRheumatol OxfYear: 200948Suppl 4iv3iv810.1093/rheumatology/kep273|
|22..||Hochberg MC. Recommendations for measurement of bone mineral density and identifying persons to be treated for osteoporosisRheum Dis Clin North AmYear: 20063268168910.1016/j.rdc.2006.09.00217288971|
|23..||Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?BoneYear: 20074130831710.1016/j.bone.2007.06.01017644058|
Claims addressed in articles 13 and 14 of the Regulation EC 1924/2006
|Article 13||Article 14|
|Article 13.1||Article 13.5|
|Referring to||the role of a nutrient or other substance in growth, development and the functions of the body||the role of a nutrient or other substance in growth, development and the functions of the body based on newly developed scientific evidence and/or which include a request for the protection of proprietary data.||the reduction of disease risk and claims relating to children's development and health|
|Application based on||generally accepted scientific evidence||submission of an extensive scientific dossier||submission of an extensive scientific dossier|
Keywords: Keywords Bone, Health claim, Nutrition, Surrogate.
Previous Document: Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of gluc...
Next Document: Advancing maternal age is associated with lower bone mineral density in young adult male offspring.